Hemantane

Hemantane (N-(2-adamantyl)hexamethyleneimine hydrochloride; gimantan) is an experimental antiparkinsonian and neuroprotective agent of the aminoadamantane structural class, synthesized and developed at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences. The compound shares the adamantane cage scaffold with the clinically established agents amantadine and memantine but is distinguished by the attachment of a seven-membered azepane (hexamethylenimine) ring at the 2-position of the adamantane nucleus, a modification that broadens the pharmacological profile relative to the parent aminoadamantanes. Hemantane acts through multiple convergent mechanisms: it is a low-affinity, noncompetitive (uncompetitive) open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor; a weak, competitive, selective inhibitor of monoamine oxidase B (MAO-B; Ki approximately 470 micromolar); a noncompetitive modulator of the dopamine transporter (DAT) that acutely reduces striatal dopamine reuptake Vmax by approximately 30 percent; a modulator of dopamine receptor subtype density (upregulating D1 and downregulating D2/D3 binding sites in the striatum after subchronic administration); and a putative sigma receptor agonist. The compound also exhibits anti-inflammatory activity in models of peripheral inflammation (acetic acid peritonitis, carrageenan-induced paw edema) and in a lipopolysaccharide-induced neuroinflammation model of Parkinson disease, where it attenuated weight loss, contralateral forepaw akinesia, and olfactory behavioral disruption.

In preclinical parkinsonism models, hemantane (10 to 20 mg/kg intraperitoneally) reduced tremor, rigidity, and oligokinesia, and was reported to be superior to the reference drug amantadine in several behavioral paradigms. In the MPTP-treated C57BL/6 mouse model, subchronic hemantane administration increased dopamine transporter levels in multiple brain structures, a response broader than that produced by amantadine. A single administration of hemantane (20 mg/kg) in C57BL/6 mice reduced striatal DOPA concentration, decreased serotonin and its metabolite levels in the striatum, and altered the homovanillic acid to dopamine ratio in the frontal cortex, demonstrating modulatory activity across both dopaminergic and serotonergic systems.

Clinical evaluation of hemantane has been conducted in a randomized, double-blind, placebo-controlled Phase 2 trial in 60 patients with newly diagnosed, untreated early-stage Parkinson disease over 16 weeks. Hemantane at 50 mg daily (25 mg twice daily) produced a 41 percent reduction in rigidity from baseline and statistically significant improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor examination scores at weeks 8, 12, and 16 compared with placebo. The 25 mg daily dose produced moderate efficacy. Safety monitoring (blood pressure, electrocardiogram, blood and urine parameters) did not identify dose-limiting toxicity at either dose. Additional preclinical research has demonstrated analgesic activity in somatic and visceral pain models, efficacy in reducing ethanol consumption in alcohol-experienced rats, attenuation of morphine withdrawal signs, and anti-arthritic activity when applied as a 5 percent topical gel formulation. The compound has not received marketing authorization in any jurisdiction and remains an investigational agent. This monograph documents the chemistry, synthesis, multi-target pharmacology, preclinical and clinical evidence, sourcing considerations, and a comparative assessment of hemantane against five structurally or mechanistically related compounds on five competency standards.